McWilliams David 4
4 · Greenwich LifeSciences, Inc. · Filed Sep 30, 2020
Insider Transaction Report
Form 4
McWilliams David
Director
Transactions
- Exercise/Conversion
Series B Preferred Stock
2020-09-29−7,663→ 0 total→ Common Stock (7,663 underlying) - Exercise/Conversion
Series C Preferred Stock
2020-09-29−3,746→ 0 total→ Common Stock (3,746 underlying) - Exercise/Conversion
Common Stock
2020-09-29+7,609→ 618,601 total - Exercise/Conversion
Common Stock
2020-09-29+7,663→ 607,246 total - Exercise/Conversion
Common Stock
2020-09-29+3,746→ 610,992 total - Exercise/Conversion
Series D Preferred Stock
2020-09-29−6,555→ 0 total→ Common Stock (6,555 underlying) - Exercise/Conversion
Series D Preferred Stock
2020-09-29−1,054→ 0 total→ Common Stock (1,054 underlying) - Other
Series D Preferred Stock
2020-09-29+1,054→ 1,054 total→ Common Stock (1,054 underlying) - Exercise/Conversion
Common Stock
2020-09-29+152,604→ 599,583 total - Exercise/Conversion
Series A Preferred Stock
2020-09-29−152,604→ 0 total→ Common Stock (152,604 underlying)
Footnotes (6)
- [F1]The Series A Preferred Stock converted into Issuer common stock on a 1-for-1 basis and had no expiration date.
- [F2]The Series B Preferred Stock converted into Issuer common stock on a 1-for-1 basis and had no expiration date.
- [F3]The Series C Preferred Stock converted into Issuer common stock on a 1-for-1 basis and had no expiration date.
- [F4]The Series D Preferred Stock converted into Issuer common stock on a 1-for-1 basis and had no expiration date.
- [F5]The Series D Preferred Stock have no expiration date and are convertible, at the option of the holder, into shares of common stock of the Issuer at the then-effective conversion rate for no additional consideration (subject to the payment of cash, if applicable, in lieu of any fractional shares in accordance with the Issuer's Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation").
- [F6]The Reporting Person was issued additional shares of Series D Preferred Stock in connection with the Issuer's initial public offering as a result of the anti-dilution protection provisions set forth in the Issuer's Certificate of Incorporation.